All In Biotech

Investigational drug · Phase 3

Anitocabtagene Autoleucel

Also called: CART-ddBCMA

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Newly Diagnosed Multiple Myeloma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

8

Any phase or sponsor naming "Anitocabtagene Autoleucel"

First trial start

2022

Jul 15, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Anitocabtagene Autoleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multiple Myeloma
  • Newly Diagnosed Multiple Myeloma

Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Anitocabtagene Autoleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.